289 related articles for article (PubMed ID: 27128833)
1. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
Salinger DH; Endres CJ; Martin DA; Gibbs MA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Timmermann S; Hall A
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
Galluzzo M; Talamonti M; D'adamio S; Bianchi L
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
Nemoto O; Hirose K; Shibata S; Li K; Kubo H
Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
11. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
12. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Attia A; Abushouk AI; Ahmed H; Gadelkarim M; Elgebaly A; Hassan Z; Abdel-Daim MM; Negida A
Clin Drug Investig; 2017 May; 37(5):439-451. PubMed ID: 28197901
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
Yamasaki K; Nakagawa H; Kubo Y; Ootaki K;
Br J Dermatol; 2017 Mar; 176(3):741-751. PubMed ID: 27106510
[TBL] [Abstract][Full Text] [Related]
18. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
19. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
